Adolor Corporation Initiates Phase 1 Study of Novel Delta Opioid Agonist for the Management of Pain; The Food and Drug Administration Reviews Complete Response and Lifts Clinical Hold.

Business Wire › August 30, 2006

Linked as:

Extract

Adolor Corporation Initiates Phase 1 Study of Novel Delta Opioid Agonist for the Management of Pain; The Food and Drug Administration Reviews Complete Response and Lifts Clinical Hold.

EXTON, Pa. -- Adolor Corporation (Nasdaq: ADLR) announced today that it has initiated a Phase 1 clinical trial of ADL5859, a novel, orally bioavailable Delta opioid receptor agonist. The Phase 1 study is designed to investigate the safe...

See the full content of this document